|
Drug Metabolism, Poor, CYP2D6-Related
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Case-control studies that assess the effects of CYPIID6 on lung cancer risk have consistently shown a mildly decreased risk for lung cancer among poor metabolizers.
|
1302563 |
1993 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Case-control studies that assess the effects of CYPIID6 on lung cancer risk have consistently shown a mildly decreased risk for lung cancer among poor metabolizers.
|
1302563 |
1993 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Case-control studies that assess the effects of CYPIID6 on lung cancer risk have consistently shown a mildly decreased risk for lung cancer among poor metabolizers.
|
1302563 |
1993 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Simple DNA based assays for the identification of individuals nulled at the CYP2D6 locus are described and have been applied to investigate whether this gene defect is associated with altered cancer susceptibility.
|
1306335 |
1992 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Simple DNA based assays for the identification of individuals nulled at the CYP2D6 locus are described and have been applied to investigate whether this gene defect is associated with altered cancer susceptibility.
|
1306335 |
1992 |
|
Autoimmune Chronic Hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine this question, genomic DNA from peripheral lymphocytes (n = 9) and liver (n = 1) of 10 patients with anti-LKM-1 antibody was analysed by Southern blot for genetic association studies between a particular CYP2D6 haplotype and autoimmune hepatitis.
|
1346512 |
1992 |
|
Autoimmune hepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine this question, genomic DNA from peripheral lymphocytes (n = 9) and liver (n = 1) of 10 patients with anti-LKM-1 antibody was analysed by Southern blot for genetic association studies between a particular CYP2D6 haplotype and autoimmune hepatitis.
|
1346512 |
1992 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of fifteen genotypes of CYP2D6 (debrisoquine 4-hydroxylase) in 53 patients with Parkinson's disease was determined by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses and compared with the findings in 72 healthy controls.
|
1349052 |
1992 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% Cl 1.51-4.28) increased risk of Parkinson's disease.
|
1350805 |
1992 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.
|
1600608 |
1992 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.
|
1600608 |
1992 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The glutathione transferase mu gene (GST1) and the debrisoquine hydroxylase gene (CYP2D6) are known to be polymorphic in the human population and have been associated with increased susceptibility to cancer.
|
1684153 |
1991 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The glutathione transferase mu gene (GST1) and the debrisoquine hydroxylase gene (CYP2D6) are known to be polymorphic in the human population and have been associated with increased susceptibility to cancer.
|
1684153 |
1991 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These studies indicate that no single mutant CYP2D6 allele as determined by EcoRI appears to be associated with lung cancer, despite the findings that these patients are invariably of the extensive metabolizer phenotype.
|
1976046 |
1990 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These studies indicate that no single mutant CYP2D6 allele as determined by EcoRI appears to be associated with lung cancer, despite the findings that these patients are invariably of the extensive metabolizer phenotype.
|
1976046 |
1990 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These studies indicate that no single mutant CYP2D6 allele as determined by EcoRI appears to be associated with lung cancer, despite the findings that these patients are invariably of the extensive metabolizer phenotype.
|
1976046 |
1990 |
|
Malignant neoplasm of urinary bladder
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 and NAT genotypes may interact in bladder cancer.
|
2011143 |
1991 |
|
Bladder Neoplasm
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 and NAT genotypes may interact in bladder cancer.
|
2011143 |
1991 |
|
Carcinoma of bladder
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 and NAT genotypes may interact in bladder cancer.
|
2011143 |
1991 |
|
Bronchogenic Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
For example CYP1A1, CYP2D6 and GST1 genotypes may have additive or multiplicative risks of bronchogenic carcinoma in cigarette smokers.
|
2011143 |
1991 |
|
Chronic active hepatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In summary, a case of autoimmune-type chronic active hepatitis is presented which is associated with a new variant of LKM antibodies reacting with a 50 kDa microsomal protein different from cytochrome P450 db1.
|
2195110 |
1990 |
|
Autoimmune Chronic Hepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |